Skip to main content
LLM 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Gareth Morgan, MD

NYU Langone Medical Center
New York, New York, United States

Dr. Morgan, director of myeloma research at NYU Langone Health’s Perlmutter Cancer Center, is a recognized international expert and thought leader on multiple myeloma and is regularly invited to give both clinical and scientific talks around the world at international meetings such as ASCO, AACR and ASH.

Dr. Morgan was involved in the molecular characterization of the Philadelphia chromosome and was the first person to apply sensitive DNA- and RNA-based PCR for the detection of minimal residual disease (MRD) in CML, and in pediatric ALL where he published the first molecular characterization of the t(11;19). These interests in both MRD and how transcription factor abnormalities and epigenetic change act as drivers of cancer progression now continue in multiple myeloma, as he believes this disease provides an excellent model system of cancer progression with which to study such events.

Dr. Morgan has published extensively on the genetics of myeloma initially utilizing FISH, SNP arrays and more recently WES and WGS, and has identified the importance of evolutionary biology in myeloma progression. To study the role played by the cells of the bone marrow microenvironment, he has explored de-convolution algorithms, applicable to RNA extracted from whole bone marrow biopsies, and, more recently, utilized high-throughput flow cytometry and single cell technologies to further define these cells.

Presentation(s):